First Actemra Multinational Phase III Trial Demonstrates Significant Improvement In Signs And Symptoms Of Rheumatoid Arthritis

... Roche announced today that 'OPTION'1, the first multinational phase III study of Actemra (tocilizumab) outside of Japan, successfully met its primary endpoint in the group of patients with moderate to severe rheumatoid arthritis (RA) who had an inadequate response to methotrexate. [click link for full article] ...